¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"exit site infection"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® infection ÇÑ±Û °¨¿°
¼³¸í   
  º´¿ø¹Ì»ý¹°ÀÌ »ç¶÷À̳ª µ¿¹° ¶Ç´Â ½Ä¹°ÀÇ Á¶Á÷. Ã¼¾×-Ç¥¸é¿¡ Á¤ÂøÇÏ¿© Áõ½ÄÇϴ »óÅÂ. ÀÌ °æ¿ì µ¿¹° ¶Ç´Â ÀÎü¿¡ ¿©·¯ °¡Áö Áõ»ó, Áï Áúº´À» ÀÏÀ¸Å°´Â °æ¿ì¿Í ÀÏÀ¸Å°Áö ¾Ê´Â °æ¿ì°¡ ÀÖ´Ù. ¿¹¸¦ µé¸é, ÀϺ»³ú¿°¹ÙÀÌ·¯½º°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Ã¼³»¿¡ Áõ½ÄÇϸ頾 »ç¶÷¿¡°Ô´Â °í¿­-µÎÅë-ÀǽÄÀå¾Ö-°æ·Ã µîÀÇ Áõ»óÀÌ ÀϾ ¹ßº´À» ¾ËÁö¸¸, ´ë´Ù¼öÀÇ »ç¶÷Àº Ã¼³»¿¡¼­ ¹ÙÀÌ·¯½º°¡ Áõ½ÄÇÏ´õ¶óµµ Áõ¼¼ÀÇ Á¤µµ°¡ ³·°í ¹ß¿­À̳ª ±× ¹ÛÀÇ Áõ¼¼µµ ¾ø¾î °¨¿°À» ¸ð¸¥´Ù. À̿͠°°ÀÌ º´¿ø¹Ì»ý¹°Àº ÀÎü¿¡ °¨¿°µÇ´õ¶óµµ ¹ßº´Çϴ °æ¿ì¿Í ÇÏÁö ¾Ê´Â °æ¿ì°¡ ÀÖ´Ù. ÀüÀÚ¸¦ Áõ»ó°¨¿°, ÈÄÀÚ¸¦ ¹«Áõ»ó°¨¿°À̶ó ÇÑ´Ù. °¨¿°ÀÇ ±Ù¿øÀÌ µÇ´Â È¯ÀÚ-º¸±ÕÀÚ-°¨¿°µ¿¹°-¸Å°³µ¿¹°-º´¿øÃ¼¸¦ Æ÷ÇÔÇÑ ¹è¼³¹° ¹× ±×¿¡ ÀÇÇØ °¨¿°µÈ °ÍÀ» °¨¿°¿øÀ̶ó Çϰí, ÀÌ·¯ÇÑ °¨¿°¿ø¿¡¼­ Á÷Á¢ ¶Ç´Â °£Á¢À¸·Î »ýü¿¡ º´¿øÃ¼°¡ Ä§ÀÔÇϴ °æ·Î¸¦ °¨¿°°æ·Î¶ó ÇÑ´Ù. °¨¿°°æ·Î¿¡´Â °ø±â°¨¿°-Á¢Ã˰¨¿°-°æ±¸°¨¿°-°æÇǰ¨¿° µîÀÌ ÀÖ´Ù. ¶ÇÇÑ °¨¿°ÁõÀº Àü¿°¼º°ú ºñÀü¿°¼ºÀÇ µÎ °¡Áö·Î ³ª´­ ¼ö ÀÖ´Ù. ÀüÀڴ Áúº´ÀÇ °æ°ú Áß¿¡(¶§·Î´Â Àẹ±â³ª È¸º¹±â¿¡) °¨¿°ÇÑ »ýüÀÇ ºÐºñ¹° ¶Ç´Â ¹è¼³¹°°ú ÇÔ²² º´¿øÃ¼°¡ ³ª¿Í¼­ Á¢ÃË ¶Ç´Â ¸Å°³¿¡ ÀÇÇØ ´Ù¸¥ °³Ã¼¸¦ °¨¿°½Ã۴ °æ¿ì¸¦ ¸»ÇÑ´Ù. ¸¶¸¶-µðÇÁÅ׸®¾Æ-¼ºÈ«¿­-Æä½ºÆ®-ÄÝ·¹¶ó-ÀÌÁú µîÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù. ÈÄÀڴ º´¿øÃ¼°¡ °¨¿°ÇÑ »ýü¿¡¼­ ¹è¼³µÇÁö ¾Ê°Å³ª ¹è¼³µÇ´õ¶óµµ ´Ù¸¥ °³Ã¼¿¡´Â °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î ¿©±â¿¡´Â ÆÄ»ódz-¸»¶ó¸®¾Æ-¹ßÁøÆ¼Çª½º-»êÈÄ¿­ µîÀÌ ÀÖ´Ù.
¿µ¹® droplet infection ÇÑ±Û ºñ¸»°¨¿°, ÀÛÀº¹æ¿ï°¨¿°
¼³¸í   
  º¸±ÕÀÚ³ª Áõ»óÀÌ Àִ ȯÀڠȤÀº À̹̠°¨¿°µÇ¾î Àִ »ç¶÷ÀǠȣÈí¿¡¼­ ³ª¿Â Á÷°æ 10¸¶ÀÌÅ©·Ð ¶Ç´Â ±× ÀÌÇÏÀÇ ¾×üÀÔÀÚ¿¡ ºÎÀ¯Çϰí Àִ º´¿øÃ¼ÀÇ ÈíÀÔ¿¡ ÀÇÇѠȣÈí±â°¨¿°À» À̸¥´Ù. ÀÎÇ÷翣ÀÚ³ª Æíµµ¿°°ú °°À̠ȯÀÚ°¡ ±âħÀ» Çϰųª ´ëÈ­ µµÁß¿¡ ÀÚÀßÇÑ ºñ¸»°ú ÇÔ²² º´¿ø±ÕÀÌ °ø±â¿Í ÇÔ²² º´¿ø±ÕÀÌ ¹æÃâµÇ¾î °ø±â¿Í ÇÔ²² È£Èí±â·Î ÈíÀÔµÊÀ¸·Î½á °¨¿°µÇ´Â °ÍÀ» ¸»ÇÑ´Ù. °áÇÙ-À¯Ç༺°¨±â-¹éÀÏÇØ-µðÇÁÅ׸®¾Æ-Æó·Å µîÀÌ ÀÌ¿¡ ÀÇÇÏ¿© ÀüÆÄµÈ´Ù.
¿µ¹® wound infection ÇÑ±Û »ó󰨿°
¼³¸í   
  Àý¼Õ µîÀÇ ±â°èÀû »óÇØ, ÀÎÀ§Àû ºÎ»ó ¶Ç´Â Å¸±ÕÀǠħÀÔ¿¡ ÀÇÇØ »óó³­ Á¶Á÷¿¡¼­ Ä§ÀÔÇÏ¿© °¨¿°½Ã۴ °Í.
¿µ¹® secondary infection ÇÑ±Û ÀÌÂ÷°¨¿°
¼³¸í   
  ¾î¶² º´¿øÃ¼ÀÇ °¨¿°¿¡ ÀÇÇÏ¿© º»ÀÎÀÇ ÀúÇ×·ÂÀÌ ¾àÇØÁ³À» ¶§ ¸öÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀÌÇÏ¿© ´Ù½Ã °¨¿°À» ÀÏÀ¸Å°´Â °Í. º´¿øÃ¼°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Æ¯Á¤ÇÑ ±â°üÀ̳ª Á¶Á÷¿¡¼­ º´¿øÃ¼°¡ Áõ½ÄÇϰí, ±×°÷¿¡ Æ¯À¯ÀÇ º´Å͸¦ ÀÏÀ¸Å°´Â °ÍÀÌ 1Â÷°¨¿° ¶Ç´Â Ãʰ¨¿°ÀÌ´Ù. ÀÌ 1Â÷°¨¿°ÀÇ º´ÅÍÀÇ º´¿øÃ¼°¡ Ç÷°ü-¸²ÇÁ°ü-±â°ü-¼ÒÈ­°ü-¿ä°ü µîÀÇ ±æÀ» µû¶ó °°Àº ±â°üÀÇ ´Ù¸¥ ºÎÀ§³ª ´Ù¸¥ ±â°üÀ¸·Î ¿î¹ÝµÇ¾î °¨¿°À» ÀÏÀ¸Å²´Ù. µû¶ó¼­ 1Â÷°¨¿°¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ ¸é¿ªÀÌ µÉ °æ¿ì¿¡´Â 2Â÷°¨¿°ÀÌ ÀϾÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, À¯Ç༺ °¨±â¿¡ °É·ÈÀ» ¶§ ¼¼±Õ¿¡ ÀÇÇÑ Æó·ÅÀÌ µÚµû¸£´Â °æ¿ì¸¦ À̸¥´Ù. Æó·Å±Õ, È­³ó¾Ë±Õ, ´ëÀå±Õ µûÀ§°¡ ÀÖ´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exit
    Ãⱸ, »çÃⱸ
  • exit dose
    Åë°ú¼±·®
  • exit wound
    1. »çÃⱸ 2. ÀÚÃⱸ
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exit
    Ãⱸ, »çÃâ
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • infection cycle
    °¨¿°°í¸®, °¨¿°»ç
  • infection
    °¨¿°
  • abortive infection
    ºÒ¹ß°¨¿°, ºÒÇö°¨¿°
  • fetal infection
    žư¨¿°
  • latent infection
    Àẹ°¨¿°
  • localized infection
    ±¹¼Ò°¨¿°
  • natural infection
    ÀÚ¿¬°¨¿°
  • neonatal infection
    °«³­¾Ö°¨¿°, ½Å»ý¾Æ°¨¿°
  • opportunistic infection
    ±âȸ°¨¿°
  • oral infection
    ÀԾȰ¨¿°, °æ±¸°¨¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exit dose
    Åë°ú¼±·®
  • exit
    Ãⱸ, »çÃâ
  • exit wound
    »çÃⱸ, ÀÚÃⱸ
  • absorption site
    Èí¼öºÎÀ§
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • definitive site
    Âø»óºÎÀ§
  • donor site
    ÁִºÎÀ§, Á¦°øºÎÀ§
  • mutational site
    µ¹¿¬º¯À̺ÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • portal of exit
    ¹èÃⱸ(ÛÉõóÏ¢).
  • portal of exit
    ¹èÃâ?ÛÉõóÏ¢).
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • fundic site
    ÀڱùٴÚÀÓ½Å
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§.
  • Borrelia recurrentis infection
    Àç±Í¿­±Õ °¨¿°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exit
    Ãⱸ(õóÏ¢), »çÃâ(ÞÒõó).
  • exit block
    ÃⱸÂ÷´Ü.
  • exit dose
    ´ëÃø·®(Óßö°åÖ), »çÃâ¼±·®.
  • exit dose
    »çÃâ¼±·®, Åë°ú¼±·®
  • exit wounds
    »çÃⱸ(ÞÒõóÏ¢), ÀÚÃⱸ(í©õóÏ¢)
  • portal of exit
    ¹èÃⱸ(ÛÉõóÏ¢).
  • portal of exit
    ¹èÃâ?ÛÉõóÏ¢).
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Abnormality by infection
    °¨¿°±âÇü
    [¿¾ ¿ë¾î] °¨¿°ºñÁ¤»ó
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • congenital infection
    ¼±Ãµ°¨¿°
  • ectopic infection
    À̼Ұ¨¿°
  • helminthic infection
    ¿¬Ãæ°¨¿°
  • household infection
    Áý¾È°¨¿°
  • indigenous infection
    ÅäÂø°¨¿°
  • infection intensity
    °¨¿°°­µµ
  • latent infection
    Àẹ°¨¿°
  • Leishmania mexicana mexicana infection
    ¸ß½ÃÄÚ¸®½´¸¸Æí¸ðÃæÁõ
  • mosquito borne infection
    ¸ð±â¸Å°³°¨¿°
  • opportunistic infection
    ±âȸ°¨¿°
  • oral infection
    °æ±¸°¨¿°
  • percutaneous infection
    °æÇǰ¨¿°
  • primary infection
    ÀÏÂ÷°¨¿°
  • protozoan infection
    ¿øÃæ°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • abortive infection
    ¹Ì¼÷°¨¿° (Ú±âÙÊïæø)
  • abortive infection
    ºÎÀü°¨¿° (ÜôîïÊïæø)
  • abortive infection
    ºÒ¿Ï°¨¿° (ÝÕèÇÊïæø)
  • cross-infection
    ±³Â÷°¨¿°(Îßó©Êïæø)
  • endosymbiotic infection
    ³»°ø»ý °¨¿° (Ò®ÍìßæÊïæø)
  • latent infection
    Àẹ°¨¿°(íÖÜÑÊïæø)
  • localized infection
    ±¹¼Ò°¨¿°(ÏÑá¶Êïæø)
  • productive infection
    »ý»ê °¨¿°(ßæß§Êïæø)
  • acceptor site
    ¼ö¿ëºÎÀ§ (â¥é»Ý»êÈ)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • amino acid attachement site
    ¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
  • aminoacyl site
    ¾Æ¹Ì³ë¾Æ½Ç ÀÚ¸®
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • site
    À§Ä¡,»çÀÌÆ®
  • web site
    À¥½ÎÀÌÆ®
  • air borne infection
    °ø±â°¨¿°, ÈíÀÔ°¨¿°
  • contagious infection
    Á¢Ã˰¨¿°, Á¢ÃËÀü¿°
  • descending infection
    ÇÏÇà°¨¿°
  • enteral infection
    Àå°ü°¨¿°
  • fungal infection
    °õÆÎÀ̰¨¿°, Áø±Õ°¨¿°
  • generalized infection
    Àü½Å°¨¿°
  • granulomatous infection
    À°¾ÆÁ¾¼º°¨¿°Áõ
  • hemolytic streptococcal infection
    ¿ëÇ÷¼º¿¬¼â±¸±Õ°¨¿°
  • hospital infection
    ¿ø³»°¨¿°, º´¿ø°¨¿°
  • infection
    °¨¿°, Àü¿°
  • meningococcal infection
    ¼ö¸·±¸±Õ°¨¿°(Áõ)
  • mixed infection
    È¥ÇÕ°¨¿°
  • periapical infection
    ±Ù÷ÁÖÀ§°¨¿°(Áõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
SSI segmental sequential irradiation; shoulder subluxation inhibition; small-scale integration; Social S...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
PEI Patient Exit Interview; phosphate excretion index; physical efficiency index; polyethyleneimine
POX point of exit
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ESI Exit-site infection
REZ root exit zone
Site 1 site
SSI Surgical Site Infection
5' SS 5' splice site
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exit wound
    »çÃⱸ
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
  • electrophilic site
    Ä£ÀüÀÚ ¹ÝÀÀ¹°
  • molecular site
    ºÐÀÚ À§
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
  • recognition site
    ÀÎ½Ä ºÎÀ§
  • site
    À§Ä¡, »çÀÌÆ®
  • site of pain modulation
    µ¿Åë Á¶Àý ºÎÀ§
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • surgical site
    ¼ö¼ú ºÎÀ§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
exit block Inability of an impulse to leave its point of origin, the mechanism for which is conceived as an encircling zone of refractory tissue denying passage to the emerging impulse.
(05 Mar 2000)
exit domain <molecular biology> One of the two main binding sites on the ribosome molecule. The finished portion of the polypeptide being translated is attached to this site and leaves the ribosome from this site when the entire polypeptide is finished.
(09 Oct 1997)
exit dose The exposure dose of radiation leaving a body opposite the portal of entry.
(05 Mar 2000)
exit pupil <microscopy> The exit pupil of a lens system is an image of the entrance pupil (hence conjugate to it) and normally should be the image of the limiting diaphragm. In both the microscope and the telescope it is the eyepoint where the beam has its smallest cross-section. It is also called the Ramsden circle or eyepoint.
(05 Aug 1998)
acceptor site The ribosomal binding site for the aminoacyl-tRNA during protein synthesis.
(05 Mar 2000)
acceptor splicing site Boundary between the right end of an intron and the left end of the adjacent exon.
Synonym: acceptor splicing site.
(05 Mar 2000)
active site <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site).
(06 May 1997)
allosteric site A specific site on a multi-subunit enzyme or other protein that is not the substrate binding site, but that when reversibly bound by an effector, induces a conformational change in the protein, altering its catalytic or binding properties.
(12 Dec 1998)
amidation site <molecular biology> A C terminus consensus sequence, required for C terminus amidation of peptides. Consensus is glycine, followed by 2 basic amino acids (arg or lys).
(18 Nov 1997)
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
apurinic site <molecular biology> Sites in DNA from which purines have been lost by cleavage of the deoxy ribose N glycosidic linkage.
(18 Nov 1997)
apyrimidinic site <molecular biology> A site on DNA where a base is missing, in this case a pyrimidine (either cytosine or thymine), but the phosphodiester backbone is still intact.
Compare: apurinic site.
(09 Oct 1997)
ATT site <molecular biology> A site on the chromosome of the bacteria E. Coli where the lambda bacteriophage can insert its genome (all of its DNA) so that it can lie dormant and have its DNA reproduced whenever the bacterium reproduces for as long as the bacterium remains healthy (that is, so that it becomes lysogenic).
(09 Oct 1997)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
exit site infection infection in the area where an artificial tube exits from the body.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infection
    ¿µÇâ; Àü¿°º´
  • droplet infection
    (ÀÇ)ºñ¸» °¨¿°
  • focal infection
    º´¼Ò°¨¿°
  • infection
    (º´µ¶ÀÇ)°ø±âÀü¿°;°¨¿°(cf.CONTAFION)(µµ´öÀûÀ¸·Î)³ª»Û °¨È­(¿µÇâ);¿À¿°(CONTAMINATION)Àü¿°º´;°¨¿°Áõ
  • infection point
    º¯°îÁ¡
  • exit
    Ãⱸ
  • exit
    Ãⱸ;ÅðÃⱸ;³ª°¨;Åð°Å;ÅðÀå;ÅðÀåÇÏ´Ù
  • exit permit
    Ãâ±¹ Çã°¡(Áõ)
  • exit poll
    ÅõÇ¥¼Ò Ãⱸ¿¡¼­ÀÇ ¿©·ÐÁ¶»ç(ÅõÇ¥°á°úÀÇ ¿¹»ó µîÀ» À§ÇÑ)
  • exit tax
    (¼Ò·Ã)(Ãâ±¹ ÀÌÁÖÀÚÀÇ)Ãâ±¹¼¼
  • exit visa
    Ãâ±¹ »çÁõ
  • fire exit
    ºñ»ó±¸;È­Àç ´ëÇDZ¸
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
  • ceru(s)site
    ¹é¿¬±¤
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á